ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
CervoMed Inc

CervoMed Inc (CRVO)

15.95
0.02
(0.13%)
Closed July 12 4:00PM
15.95
0.00
( 0.00% )
Pre Market: 4:09AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
15.95
Bid
6.42
Ask
17.58
Volume
-
0.00 Day's Range 0.00
4.22 52 Week Range 26.3789
Market Cap
Previous Close
15.95
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
44,771
Shares Outstanding
8,253,741
Dividend Yield
-
PE Ratio
-16.72
Earnings Per Share (EPS)
-0.26
Revenue
7.15M
Net Profit
-2.17M

About CervoMed Inc

Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
CervoMed Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRVO. The last closing price for CervoMed was $15.95. Over the last year, CervoMed shares have traded in a share price range of $ 4.22 to $ 26.3789.

CervoMed currently has 8,253,741 shares outstanding. The market capitalization of CervoMed is $131.65 million. CervoMed has a price to earnings ratio (PE ratio) of -16.72.

CRVO Latest News

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE...

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its...

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024...

CervoMed to Appoint William Elder as Chief Financial Officer

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the...

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q...

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash...

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million...

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.79-4.719235364416.7417.489914.516955415.49400654CS
4-2.75-14.705882352918.722.5714.517859018.29586435CS
12-8.05-33.54166666672425.6914.514477119.82969733CS
266.7673.55821545169.1926.37898.013570718.55544531CS
522.4518.148148148113.526.37894.223717313.03873539CS
1562.4518.148148148113.526.37894.223717313.03873539CS
2602.4518.148148148113.526.37894.223717313.03873539CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DJTTrump Media and Technology Group Corporation
$ 53.80
(74.17%)
1.11M
PHUNPhunware Inc
$ 9.10
(56.09%)
234.11k
INTZIntrusion Inc
$ 1.74
(45.00%)
266
CPOPPop Culture Group Company Ltd
$ 1.86
(44.19%)
127.38k
DATSDatChat Inc
$ 1.39
(33.65%)
77.07k
EASTEastside Distilling Inc
$ 1.00
(-16.67%)
14.82k
QLGNQualigen Therapeutics Inc
$ 0.365
(-15.92%)
314.53k
IVPInspire Veterinary Partners Inc
$ 9.00
(-14.85%)
11.58k
KZIAKazia Therapeutics Ltd
$ 0.7796
(-12.97%)
89.21k
VEVVicinity Motor Corporation
$ 0.63
(-11.65%)
44.85k
MAXNMaxeon Solar Technologies Ltd
$ 0.2209
(-6.99%)
1.17M
DJTTrump Media and Technology Group Corporation
$ 53.79
(74.13%)
1.12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 15.48
(10.41%)
366.95k
QLGNQualigen Therapeutics Inc
$ 0.365
(-15.92%)
314.77k
PHUNPhunware Inc
$ 9.13
(56.60%)
234.46k

CRVO Discussion

View Posts

Your Recent History

Delayed Upgrade Clock